These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12904058)

  • 1. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.
    Jagoda E; Contoreggi C; Lee MJ; Kao CH; Szajek LP; Listwak S; Gold P; Chrousos G; Greiner E; Kim BM; Jacobson AE; Rice KC; Eckelman W
    J Med Chem; 2003 Aug; 46(17):3559-62. PubMed ID: 12904058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
    Li YW; Hill G; Wong H; Kelly N; Ward K; Pierdomenico M; Ren S; Gilligan P; Grossman S; Trainor G; Taub R; McElroy J; Zazcek R
    J Pharmacol Exp Ther; 2003 Apr; 305(1):86-96. PubMed ID: 12649356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor.
    Jagoda EM; Lang L; McCullough K; Contoreggi C; Kim BM; Ma Y; Rice KC; Szajek LP; Eckelman WC; Kiesewetter DO
    Synapse; 2011 Sep; 65(9):910-8. PubMed ID: 21308801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.
    Wilson AA; McCormick P; Kapur S; Willeit M; Garcia A; Hussey D; Houle S; Seeman P; Ginovart N
    J Med Chem; 2005 Jun; 48(12):4153-60. PubMed ID: 15943487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide.
    Parent EE; Jenks C; Sharp T; Welch MJ; Katzenellenbogen JA
    Nucl Med Biol; 2006 Aug; 33(6):705-13. PubMed ID: 16934689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of [11C]MPEPy as a potential PET ligand for mGlu5 receptors.
    Severance AJ; Parsey RV; Kumar JS; Underwood MD; Arango V; Majo VJ; Prabhakaran J; Simpson NR; Van Heertum RL; Mann JJ
    Nucl Med Biol; 2006 Nov; 33(8):1021-7. PubMed ID: 17127176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents.
    Huang Y; Bae SA; Zhu Z; Guo N; Roth BL; Laruelle M
    J Med Chem; 2005 Apr; 48(7):2559-70. PubMed ID: 15801845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
    Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
    J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain.
    Pierson ME; Andersson J; Nyberg S; McCarthy DJ; Finnema SJ; Varnäs K; Takano A; Karlsson P; Gulyás B; Medd AM; Lee CM; Powell ME; Heys JR; Potts W; Seneca N; Mrzljak L; Farde L; Halldin C
    Neuroimage; 2008 Jul; 41(3):1075-85. PubMed ID: 18434202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5.
    Lucatelli C; Honer M; Salazar JF; Ross TL; Schubiger PA; Ametamey SM
    Nucl Med Biol; 2009 Aug; 36(6):613-22. PubMed ID: 19647167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and initial PET imaging of new potential NK1 receptor radioligands 1-[2-(3,5-bis-trifluoromethyl-benzyloxy)-1-phenyl-ethyl]-4-[11C]methyl-piperazine and {4-[2-(3,5-bis-trifluoromethyl-benzyloxy)-1-phenyl-ethyl]-piperazine-1-yl}-acetic acid [11C]methyl ester.
    Gao M; Mock BH; Hutchins GD; Zheng QH
    Nucl Med Biol; 2005 Jul; 32(5):543-52. PubMed ID: 15982585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand.
    Airaksinen AJ; Jablonowski JA; van der Mey M; Barbier AJ; Klok RP; Verbeek J; Schuit R; Herscheid JD; Leysen JE; Carruthers NI; Lammertsma AA; Windhorst AD
    Nucl Med Biol; 2006 Aug; 33(6):801-10. PubMed ID: 16934699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography.
    Willis PG; Pavlova OA; Chefer SI; Vaupel DB; Mukhin AG; Horti AG
    J Med Chem; 2005 Sep; 48(18):5813-22. PubMed ID: 16134948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin-3, INSL5, and their receptors.
    Liu C; Lovenberg TW
    Results Probl Cell Differ; 2008; 46():213-37. PubMed ID: 18236022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
    Deng H; Gifford AN; Zvonok AM; Cui G; Li X; Fan P; Deschamps JR; Flippen-Anderson JL; Gatley SJ; Makriyannis A
    J Med Chem; 2005 Oct; 48(20):6386-92. PubMed ID: 16190764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor.
    Evens N; Bosier B; Lavey BJ; Kozlowski JA; Vermaelen P; Baudemprez L; Busson R; Lambert DM; Van Laere K; Verbruggen AM; Bormans GM
    Nucl Med Biol; 2008 Oct; 35(7):793-800. PubMed ID: 18848664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor.
    Martarello L; Kilts CD; Ely T; Owens MJ; Nemeroff CB; Camp M; Goodman MM
    Nucl Med Biol; 2001 Feb; 28(2):187-95. PubMed ID: 11295429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists.
    Hsin LW; Tian X; Webster EL; Coop A; Caldwell TM; Jacobson AE; Chrousos GP; Gold PW; Habib KE; Ayala A; Eckelman WC; Contoreggi C; Rice KC
    Bioorg Med Chem; 2002 Jan; 10(1):175-83. PubMed ID: 11738619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
    Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
    J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.